Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 2/14/2019 |
| Start Date: | November 12, 2008 |
| End Date: | December 31, 2019 |
A Phase I Open Label, Multi Centre Study of AZD2281 Administered Orally in Combination With Cisplatin, to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours
A Phase I study to assess the safety and tolerability of AZD2281 in combination with
Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to
establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with
advanced solid tumours. Approximately 50 (max 60) patients from 2 countries will be enrolled.
Cisplatin in patients with advanced Solid Tumours. This is an open label-dose finding; to
establish the maximum tolerated dose of AZD2281 combined with Cisplatin in patients with
advanced solid tumours. Approximately 50 (max 60) patients from 2 countries will be enrolled.
Inclusion Criteria:
- Life expectancy of at least 12 weeks
- Histologically confirmed metastatic cancer, not amenable to surgery or radiation
therapy with curative intent
- Patients with measurable or non measurable disease according to RECIST
Exclusion Criteria:
- Less than 28 days from active therapy (ie any treatment used to treat the disease) or
high dose radiotherapy
- Brain Metastases or spinal cord compression unless irradiated at least 4 weeks before
entry and stable without steroid treatment for >1 week
- Persistent CTCAE Grade 2 or greater toxicities (excluding alopecia) caused by prior
therapy
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials